Press Releases

Date Title and Summary Additional Formats
Toggle Summary NOVELOS THERAPEUTICS PRICES $5.5 MILLION PUBLIC OFFERING
NOVELOS THERAPEUTICS PRICES $5.5 MILLION PUBLIC OFFERING MADISON, Wisc. (February 13, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the pricing of a public offering of 11,000,000 units at
View HTML
Toggle Summary NOVELOS THERAPEUTICS TO PRESENT AT THE 15th ANNUAL BIO CEO & INVESTOR CONFERENCE ON FEBRUARY 11
NOVELOS THERAPEUTICS TO PRESENT AT THE 15th ANNUAL BIO CEO & INVESTOR CONFERENCE ON FEBRUARY 11 MADISON, Wisc. (February 4, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry S.
View HTML
Toggle Summary NOVELOS THERAPEUTICS PRESENTS DIAPEUTIC TECHNOLOGY PLATFORM AT EMIT: TARGETED RADIOTHERAPY INTERNATIONAL CONFERENCE
NOVELOS THERAPEUTICS PRESENTS DIAPEUTIC TECHNOLOGY PLATFORM AT EMIT: TARGETED RADIOTHERAPY INTERNATIONAL CONFERENCE Oral Presentation Highlights Cancer-Targeted PET Imaging, Therapeutic and Optical Imaging Compounds that Offer Broad-Spectrum Diagnosis and Treatment of Solid Tumors MADISON, Wisc.
View HTML
Toggle Summary NOVELOS THERAPEUTICS TO PRESENT AT THE BENCHMARK 2012 MICRO CAP DISCOVERY INVESTOR CONFERENCE ON NOVEMBER 29
NOVELOS THERAPEUTICS TO PRESENT AT THE BENCHMARK 2012 MICRO CAP DISCOVERY INVESTOR CONFERENCE ON NOVEMBER 29 MADISON, Wisc. (November 27, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that
View HTML
Toggle Summary NOVELOS THERAPEUTICS CLOSES $2 MILLION PRIVATE PLACEMENT
NOVELOS THERAPEUTICS CLOSES $2 MILLION PRIVATE PLACEMENT Initiates Build-out of Manufacturing Facility for I-124-CLR1404 (LIGHT) MADISON, Wisc. (November 5, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer,
View HTML
Toggle Summary NOVELOS THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN SOLID TUMOR IMAGING TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER
NOVELOS THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN SOLID TUMOR IMAGING TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER Expects Initial Imaging Results in First Quarter 2013 MADISON, Wisc. (October 25, 2012) – Novelos Therapeutics, Inc.
View HTML
Toggle Summary NOVELOS THERAPEUTICS AND ACADEMIC COLLABORATORS PRESENT DIAPEUTIC TECHNOLOGY PLATFORM AT IMAGING IN 2020 CONFERENCE
NOVELOS THERAPEUTICS AND ACADEMIC COLLABORATORS PRESENT DIAPEUTIC TECHNOLOGY PLATFORM AT IMAGING IN 2020 CONFERENCE Cancer-Targeted PET Imaging, Therapeutic and Optical Imaging Compounds Offer Broad-Spectrum Diagnosis and Treatment of Solid Tumors MADISON, Wisc.
View HTML
Toggle Summary NOVELOS THERAPEUTICS TO PRESENT AT 11th ANNUAL BIO INVESTOR FORUM ON OCTOBER 10
NOVELOS THERAPEUTICS TO PRESENT AT 11th ANNUAL BIO INVESTOR FORUM ON OCTOBER 10 MADISON, Wisc. (October 2, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, President and
View HTML
Toggle Summary NOVELOS THERAPEUTICS SUCCESSFULLY COMPLETES SECOND COHORT IN PHASE 1b SOLID TUMOR TRIAL WITH I-131-CLR1404 (HOT) CANCER-TARGETED MOLECULAR RADIOTHERAPEUTIC
NOVELOS THERAPEUTICS SUCCESSFULLY COMPLETES SECOND COHORT IN PHASE 1b SOLID TUMOR TRIAL WITH I-131-CLR1404 (HOT) CANCER-TARGETED MOLECULAR RADIOTHERAPEUTIC Additional Clinical Results Expected in Q1 2013 MADISON, Wisc. (September 11, 2012) – Novelos Therapeutics, Inc.
View HTML
Toggle Summary NOVELOS THERAPEUTICS AND ACADEMIC COLLABORATORS PRESENT THREE POSTERS AT 2012 WORLD MOLECULAR IMAGING CONGRESS
NOVELOS THERAPEUTICS AND ACADEMIC COLLABORATORS PRESENT THREE POSTERS AT 2012 WORLD MOLECULAR IMAGING CONGRESS Cancer-Targeted Therapeutic I-131-CLR1404 (HOT) and Diagnostic I-124-CLR1404 (LIGHT) Demonstrate Selective and Prolonged Uptake in a Range of Tumor Types MADISON, Wisc.
View HTML